Join us for a virtual event with Calliditas Therapeutics, featuring its partner Everest Medicines, following the China National Medical Products Administration’s (NMPA) acceptance of Everest Medicines’ new drug application (NDA) for Nefecon. The event will feature Rogers Yongqing Luo, Everest Medicines’ new Chief Executive Officer, and Zhengying Zhu, M.D., PhD, Chief Medical Officer, Internal Medicine, who will discuss unmet medical needs in IgA Nephropathy (IgAN) treatment and the market opportunity in China.

A live Q&A session will follow the formal presentations.